GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 136 Note 19 : Other equity ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Capital redemption reserve 2,61.95 2,61.95 General reserve 790,74.14 790,74.14 Capital reserve (Refer Note 57) (19,12.47) (19,16.47) Retained earnings (Including Other Comprehensive Income) 1733,97.52 553,51.28 2508,21.14 1327,70.90 Note 20 : Non-current financial liabilities - Lease liabilities ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Lease liabilities (Refer Note 48) 7,62.35 20,24.99 7,62.35 20,24.99 Note 21 : Non-current financial liabilities - Others ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Security deposits received (Unsecured) 2,04.46 2,04.46 2,04.46 2,04.46 Note 22 : Non-current provisions ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 For Pricing matters (Refer Note 29 and 43) 122,70.82 122,70.82 For employee benefits (Refer Note 41) Gratuity 17,68.11 16,98.96 Leave encashment and compensated absences 36,74.38 34,94.48 Post retirement medical and other benefits 61,78.92 62,85.22 For long term incentive plan (Refer Note 29 and 54) 4,14.14 2,85.61 For divestment / restructuring (Refer Note 29) 1,92.96 1,92.96 For others (Refer Note 29) 15,96.50 15,96.50 260,95.83 258,24.55 Note 23 : Current Borrowings ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Current Maturity of Interest free deferred sales tax incentive - 2.40 - 2.40 Terms of repayment Interest free deferred sales tax incentive as at March 31, 2022 of ` Nil lakhs (March 31, 2021: ` 2.40 lakhs) availed under the 1993 Sales Tax Deferment Scheme.